⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

September 29, 2021Clinical Gastroenterology and HepatologyOpen Access

Efficacy and Safety of 2 Vedolizumab Intravenous Regimens for Perianal Fistulizing Crohn’s Disease: ENTERPRISE Study

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

gov no: NCT02630966; EudraCT: 2015-000852-12.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Schwartz et al. (2021) studied this question.

synapsesocial.com/papers/69d8ace78c03fbaff8befdcb https://doi.org/10.1016/j.cgh.2021.09.028

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn's diseaseNarrative Review · 2014 · 425 citations
2Endpoints for Perianal Crohn’s Disease Trials: Past, Present and FutureRCT · 2021 · 33 citations
3A clinical decision support tool may help to optimise vedolizumab therapy in Crohn’s diseaseCohort Study · 2019 · 54 citations
4Magnetic resonance imaging may predict deep remission in patients with perianal fistulizing Crohn's diseaseOriginal Research · 2017 · 39 citations
5Vedolizumab as Induction and Maintenance Therapy for Crohn's DiseaseRCT · 2013 · 2,735 citations